Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study

[1] Goadsby PJ(2002)Migraine—current understanding and treatment N Engl J Med 346 257-270

[2] Lipton RB(2022)Migraine: a review on its history, global epidemiology, risk factors, and comorbidities Front Neurol 396 1204-1222

[3] Ferrari MD(2020)Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet 23 34-187

[4] Amiri P(2022)The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates J Headache Pain 28 183-32

[5] Kazeminasab S(1990)Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 12 1612-124

[6] Nejadghaderi SA(2022)Gepants for acute and preventive migraine treatment: a narrative review Brain Sci 59 20-6

[7] Vos T(2019)Targeting CGRP for the prevention of migraine and cluster headache: a narrative review Headache 52 83-2760

[8] Lim SS(2013)Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies Clin Pharmacokinet 2 1-1742

[9] Abbafati C(2020)Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor Neurol Res Pract 10 2751-67

[10] Stovner LJ(2017)Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab J Pain Res 60 1734-265

[1] Goadsby PJ(2002)Migraine—current understanding and treatment N Engl J Med 346 257-270

[2] Lipton RB(2022)Migraine: a review on its history, global epidemiology, risk factors, and comorbidities Front Neurol 396 1204-1222

[3] Ferrari MD(2020)Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Lancet 23 34-187

[4] Amiri P(2022)The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates J Headache Pain 28 183-32

[5] Kazeminasab S(1990)Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 12 1612-124

[6] Nejadghaderi SA(2022)Gepants for acute and preventive migraine treatment: a narrative review Brain Sci 59 20-6

[7] Vos T(2019)Targeting CGRP for the prevention of migraine and cluster headache: a narrative review Headache 52 83-2760

[8] Lim SS(2013)Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies Clin Pharmacokinet 2 1-1742

[9] Abbafati C(2020)Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor Neurol Res Pract 10 2751-67

[10] Stovner LJ(2017)Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab J Pain Res 60 1734-265